Authorized purpose: Concurrent CADe support for identifying, categorizing, and highlighting suspicious regions of interest in the Lungs, Pleura, Cardiac, and Hardware categories on chest radiographs for radiologist review.
Clinical role
Concurrent-reader CADe detection, category classification, localization, and highlighting of suspicious chest-radiograph ROIs.
Images and patients
X-ray/Radiography · Chest: lungs, pleura, cardiac structures, and hardware
Key limitation
Keep in mind: The device is an adjunct and not the primary interpretation; radiologists must review the annotated and original unannotated images. It does not make treatment recommendations or provide a diagnosis and is not designed to detect conditions outside the four listed categories; the labeled population is adults and transitional adolescents treated as adults.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent CADe support for identifying, categorizing, and highlighting suspicious regions of interest in the Lungs, Pleura, Cardiac, and Hardware categories on chest radiographs for radiologist review.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest: lungs, pleura, cardiac structures, and hardware Input: Adult frontal chest radiographs in DICOM format from adults and transitional adolescents aged 18 to under 22 years who are treated like adults.
Who uses it?Intended users: Radiologists.
What does the software produce?Output: A secondary-capture DICOM image containing the original radiograph, manufacturer/product/version information, color-coded bounding boxes for suspected Lungs, Pleura, Cardiac, or Hardware ROIs, or a 'No Suspicious ROI(s) Detected' message when no boxes are present; workflow errors are logged.
What is its most important limitation?Key limitation: The device is an adjunct and not the primary interpretation; radiologists must review the annotated and original unannotated images. It does not make treatment recommendations or provide a diagnosis and is not designed to detect conditions outside the four listed categories; the labeled population is adults and transitional adolescents treated as adults.
Clinical takeaway. Clinical role: Concurrent CADe support for identifying, categorizing, and highlighting suspicious regions of interest in the Lungs, Pleura, Cardiac, and Hardware categories on chest radiographs for radiologist review.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: standalone testing used 3,000 scans (2,000 NIH and 1,000 Segmed) with three U.S. board-certified radiologists establishing majority ground truth. Image-level standalone sensitivity/specificity/AUROC by category were Lungs 0.903/0.937/0.971, Pleura 0.924/0.897/0.964, Cardiac 0.924/0.930/0.978, Hardware 0.947/0.947/0.980, and aggregate 0.926/0.933/0.974. ROI-level wAFROC-FOM was aggregate 0.920. The 300-image, 24-reader MRMC study from 13 U.S. hospitals found aggregate aided wAFROC-FOM 0.893 (95% CI 0.871-0.914) versus unaided 0.821 (0.791-0.852), p<0.0001; reader sensitivity/specificity were separate aided/unaided endpoints.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent CADe support for identifying, categorizing, and highlighting suspicious regions of interest in the Lungs, Pleura, Cardiac, and Hardware categories on chest radiographs for radiologist review.
A secondary-capture DICOM image containing the original radiograph, manufacturer/product/version information, color-coded bounding boxes for suspected Lungs, Pleura, Cardiac, or Hardware ROIs, or a 'No Suspicious ROI(s) Detected' message when no boxes are present; workflow errors are logged.
Radiologist chest-radiograph reading workflow; the clinical reader study used 13 U.S. hospitals, but the FDA packet does not define all facility types.
The device is an adjunct and not the primary interpretation; radiologists must review the annotated and original unannotated images. It does not make treatment recommendations or provide a diagnosis and is not designed to detect conditions outside the four listed categories; the labeled population is adults and transitional adolescents treated as adults.
FDA packet: standalone testing used 3,000 scans (2,000 NIH and 1,000 Segmed) with three U.S. board-certified radiologists establishing majority ground truth. Image-level standalone sensitivity/specificity/AUROC by category were Lungs 0.903/0.937/0.971, Pleura 0.924/0.897/0.964, Cardiac 0.924/0.930/0.978, Hardware 0.947/0.947/0.980, and aggregate 0.926/0.933/0.974. ROI-level wAFROC-FOM was aggregate 0.920. The 300-image, 24-reader MRMC study from 13 U.S. hospitals found aggregate aided wAFROC-FOM 0.893 (95% CI 0.871-0.914) versus unaided 0.821 (0.791-0.852), p<0.0001; reader sensitivity/specificity were separate aided/unaided endpoints.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: standalone testing used 3,000 scans (2,000 NIH and 1,000 Segmed) with three U.S. board-certified radiologists establishing majority ground truth. Image-level standalone sensitivity/specificity/AUROC by category were Lungs 0.903/0.937/0.971, Pleura 0.924/0.897/0.964, Cardiac 0.924/0.930/0.978, Hardware 0.947/0.947/0.980, and aggregate 0.926/0.933/0.974. ROI-level wAFROC-FOM was aggregate 0.920. The 300-image, 24-reader MRMC study from 13 U.S. hospitals found aggregate aided wAFROC-FOM 0.893 (95% CI 0.871-0.914) versus unaided 0.821 (0.791-0.852), p<0.0001; reader sensitivity/specificity were separate aided/unaided endpoints.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
DeepTek CXR analyzer v1.0 regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231001
Samplen=3000
IndependenceIndependence not established
K231001
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231001. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Adult frontal chest radiographs in DICOM format from adults and transitional adolescents aged 18 to under 22 years who are treated like adults.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet describes configurable PACS connectivity using AE Title, IP address, listener and sender ports, DICOM chest-radiograph input from the configured PACS, and secondary-capture DICOM output returned to that PACS; it does not establish universal PACS/RIS/EHR compatibility.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the DeepTek CXR Analyzer platform as secure on-premise processing and delivery of chest radiographs. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Platform Secure on-premise processing and Secure cloud-based processing and delivery of chest radiographs delivery of chest radiographs" … "Feature/ Proposed Device Predicate Device Function DeepTek CXR Analyzer Chest-CAD (K210666)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: A secondary-capture DICOM image containing the original radiograph, manufacturer/product/version information, color-coded bounding boxes for suspected Lungs, Pleura, Cardiac, or Hardware ROIs, or a 'No Suspicious ROI(s) Detected' message when no boxes are present; workflow errors are logged.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A secondary-capture DICOM image containing the original radiograph, manufacturer/product/version information, color-coded bounding boxes for suspected Lungs, Pleura, Cardiac, or Hardware ROIs, or a 'No Suspicious ROI(s) Detected' message when no boxes are present; workflow errors are logged.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the DeepTek CXR Analyzer platform as secure on-premise processing and delivery of chest radiographs. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Platform Secure on-premise processing and Secure cloud-based processing and delivery of chest radiographs delivery of chest radiographs" … "Feature/ Proposed Device Predicate Device Function DeepTek CXR Analyzer Chest-CAD (K210666)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA packet describes configurable PACS connectivity using AE Title, IP address, listener and sender ports, DICOM chest-radiograph input from the configured PACS, and secondary-capture DICOM output returned to that PACS; it does not establish universal PACS/RIS/EHR compatibility.
DeepTek's regulatory page states that its products and services are designed and developed with security as a high priority and claims compliance with global security standards and regulations including ISO 27001, GDPR, and HIPAA; the same page names CXR Analyzer among its US FDA 510(k)-cleared solutions.
Vendor-wide
Checked 2026-10-27
Vendor statement; no certificates read. Company-level statement applied to DeepTek Medical Imaging Pvt Ltd entries. Exact-release scope is not established.
ACR AI Central provides an exact-submission model card for DeepTek CXR Analyzer v1.0; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K231001 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: Analyze frontal chest and abdominal X-ray images to detect and localize a nasally or orally inserted enteric tube, its tip and side port if present, and the diaphragm and airways for radiologist review.
Modality
X-ray/Radiography
Anatomy
Chest/lung and abdomen/stomach; enteric tube, tube tip and side port, diaphragm, and airways including carina and left/right bronchi
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.